Amwell (NYSE: AMWL) reported Q4 EPS of $. Revenue for the quarter came in at $60.4 million versus the consensus estimate of $51.23 million.

“Our fourth quarter results were strong across all of our performance metrics, closing out a year of significant growth. Throughout 2020, the pandemic stressed the entire healthcare system and drove a rapid evolution in the way care is delivered from simple and convenient urgent care replacement service to a mission critical, digital care delivery infrastructure across the full continuum of care. This change is profound and irreversible in our opinion and we were thrilled to see our platform embraced by our clients’ providers across the community and used in ways that strengthens existing patient provider relationships. The Amwell platform was able to support overall care delivery in the new hybrid world by rapidly launching new modules and care points like Amwell Now, the Amwell Connect EHR module and the home and hospital enabled C500 Carepoint,” said Dr. Ido Schoenberg, Chairman and Co-CEO.

Dr. Schoenberg continued, “Responding to the post-pandemic market’s demand to use telehealth in a new, much more comprehensive, scalable and sophisticated way, we are accelerating our investment in our technology platform and its modules and programs. We help our clients and partners enable hybrid care models that support both episodic and longitudinal care. We also work to offer much greater diversity of use cases and solutions on our platform by accommodating innovations of third parties as well as our clients and partners.”

GUIDANCE:

Amwell sees FY2021 revenue of $260-270 million, versus the consensus of $269.77 million.

The company is providing the initial outlook for 2021 and expects:

• Revenue between $260 and $270 million
• AMG visits between 1.5 and 1.7 million
• Adjusted EBITDA between $(157) million and $(147) million

For earnings history and earnings-related data on Amwell (AMWL) click here.